Incyte Q1 net income doubles to $303M on strong product growth; JAKAFI XR launch expected mid-2026

Filed April 28, 2026 · Period ending March 31, 2026 · Compared to 10-Q Apr 29, 2025 · ~2 min read

Key Changes

• high

  Net income nearly doubled to $303M ($1.47/share diluted) vs $158M ($0.80/share) in Q1 2025, driven by JAKAFI sales up 7% to $758M, OPZELURA up 20% to $143M, and strong uptake of newer products NIKTIMVO ($55M) and ZYNYZ ($41M).

  MD&A: Financial Results verify on EDGAR →
• high

  JAKAFI XR (once-daily extended release) bioequivalence study completed and FDA response submitted; regulatory decision and potential commercial launch anticipated mid-2026, which could improve patient compliance and extend franchise life.

  MD&A: JAKAFI XR Update verify on EDGAR →
• high

  FDA granted Breakthrough Therapy designation to INCA033989 for essential thrombocythemia with CALR mutation; Phase 3 registrational study on track to start mid-2026, accelerating path to potential approval in underserved MPN population.

  MD&A: INCA033989 Development verify on EDGAR →